Adaptive Radiotherapy + Hormone Therapy for Prostate Cancer
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had systemic chemotherapy within 3 years prior to treatment start, and you must not have prior androgen deprivation therapy unless it started within 60 days before treatment. It's best to discuss your current medications with the trial team.
What data supports the idea that Adaptive Radiotherapy + Hormone Therapy for Prostate Cancer is an effective treatment?
The available research shows that adding stereotactic ablative radiotherapy (SABR) to standard treatment for prostate cancer can slow the disease's growth and improve survival rates. For instance, the ORIOLE trial found that SABR slowed disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay further hormone therapy. Additionally, the SABR-COMET trial reported a significant improvement in overall survival for patients treated with SABR. These findings suggest that combining adaptive radiotherapy with hormone therapy can be an effective treatment for prostate cancer.12345
What safety data exists for adaptive radiotherapy and hormone therapy in prostate cancer treatment?
The safety data for adaptive radiotherapy, including stereotactic body radiation therapy (SBRT) and stereotactic ablative radiotherapy (SABR), combined with hormone therapy (ADT) for prostate cancer, indicates that these treatments are generally safe and effective. In a study of 400 patients treated with SABR, no severe late adverse effects were observed, and only a small percentage experienced acute reactions. Another study comparing SBRT to conventional therapy found SBRT to be a promising non-invasive alternative with potential benefits in quality of life and reduced toxicity. Long-term data from a 7-year study also supports the safety and effectiveness of SBRT, showing excellent disease control with manageable toxicity levels.678910
Is Adaptive Stereotactic Body Radiation Therapy a promising treatment for prostate cancer?
What is the purpose of this trial?
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.
Research Team
Amit Bhatt, M.D., Ph.D.
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
Men over 18 with high-risk or unfavorable intermediate-risk prostate cancer, who haven't had prior treatments like chemotherapy or radical prostatectomy in the last 3 years. They should have an ECOG performance status ≤1, no evidence of metastatic disease, and be able to start hormone therapy within 60 days of radiation treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Adaptive stereotactic body radiotherapy (SBRT) with simultaneous integrated boosts to the prostate and MR-detected nodules
Androgen Deprivation Therapy (ADT)
ADT administered according to institutional standard, with a minimum of 4 months for intermediate-risk and 1 year for high-risk disease
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of biochemical recurrence and overall survival
Treatment Details
Interventions
- Adaptive Stereotactic Body Radiation Therapy
- Androgen deprivation therapy
Adaptive Stereotactic Body Radiation Therapy is already approved in European Union, United States, Canada for the following indications:
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester